Findings from the ATLAS ACS TIMI 46 study - a phase-II study of the novel oral anticoagulant Xarelto (rivaroxaban) - were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008 in New Orleans by C Michael Gibson, director of the TIMI Data Coordinating Center, Harvard Medical School, Boston, Massachusetts, USA. Results from this phase-II study support moving rivaroxaban into a pivotal phase-III trial for the secondary prevention of acute coronary syndrome (ACS) later this year.
The details can be read here.
No comments:
Post a Comment